HLF Aidi injection combined with chemotherapy in the treatment of liver cancer observed.docVIP

 PAGE \* MERGEFORMAT 4 HLF Aidi injection combined with chemotherapy in the treatment of liver cancer observed [Abstract] Objective To evaluate the HLF Aidi injection combined with chemotherapy, the clinical efficacy of primary liver cancer. Methods Clinical data: 138 cases were 2004 6 Zhi June 2008 hospital cases. Were randomly divided into treatment group and control group, treatment methods: All cases for the first time the Ministry of treatment, were selected HLF systemic chemotherapy, two-cycle assessment. Treatment group while giving the Aidi injection (Bai Yi Pharmaceutical Co., Ltd., Guizhou production) 50ml, intravenous infusion of a cycle of 15 days, rest 1 week repeat, 2-cycle assessment. Conclusion This study HLF, said Ming Aidi injection combined with chemotherapy in the treatment of liver cancer has a good effect, with attenuated efficiency, enhance anti-cancer effects, and comprehensively improve the quality of life characteristics. [Keywords:] Aidi injection chemotherapy for hepatocellular carcinoma 1 Introduction Primary hepatocellular carcinoma (HCC) is currently considered the most evil of the tumor, the general incidence of death an average of 3-6 months, according to WHO and other reports, HCC incidence is estimated that each year at least 100 million new patients, their death index (mortality index ) to 0.94 [1]. Therefore, the study has attracted worldwide attention for its treatment. This understanding of traditional Chinese medicine Aidi injection combined with chemotherapy in HCC in the role. Now report on the results as follows: Data mode 2 2.1 The clinical data of 138 cases were in June 2003 -2006 year in June at the hospital cases. The clinical images, alpha-fetoprotein (AFP) test or pathologically confirmed diagnosis, expected survival 3 months II, III in patients. Were randomly divided into treatment group and control group, treatment group 70 cases, male 60 cases, female 10 cases, with an average age of 62.5 years, control